Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1974 1
1978 1
1980 2
1989 1
1991 1
1992 2
1993 2
1994 1
1995 1
1997 2
1998 1
1999 1
2000 2
2002 1
2003 2
2005 1
2007 3
2008 2
2009 3
2010 2
2011 2
2012 1
2013 5
2014 3
2015 4
2016 2
2017 3
2018 4
2019 1
2020 2
2021 3
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Mild hemophilia A.
Franchini M, Favaloro EJ, Lippi G. Franchini M, et al. J Thromb Haemost. 2010 Mar;8(3):421-32. doi: 10.1111/j.1538-7836.2009.03717.x. Epub 2009 Dec 7. J Thromb Haemost. 2010. PMID: 19995408 Free article. Review.
Mild hemophilia A (HA), defined by clinical features and factor VIII coagulant activity (FVIII:C) between 0.05 and 0.40 IU mL(-1), is characteristically distinct from severe HA. ...
Mild hemophilia A (HA), defined by clinical features and factor VIII coagulant activity (FVIII:C) between 0.05 and 0.40 …
Hemophilia A in the third millennium.
Franchini M, Mannucci PM. Franchini M, et al. Blood Rev. 2013 Jul;27(4):179-84. doi: 10.1016/j.blre.2013.06.002. Epub 2013 Jun 28. Blood Rev. 2013. PMID: 23815950 Review.
According to the degree of FVIII deficiency, mild, moderate or severe forms are recognized. Although patients with mild hemophilia A usually bleed excessively only after trauma or surgery, those with severe hemophilia experience frequent episodes of spontaneo …
According to the degree of FVIII deficiency, mild, moderate or severe forms are recognized. Although patients with mild hemophilia …
Emerging Issues in Diagnosis, Biology, and Inhibitor Risk in Mild Hemophilia A.
Castaman G, Eckhardt C, van Velzen A, Linari S, Fijnvandraat K. Castaman G, et al. Semin Thromb Hemost. 2016 Jul;42(5):507-12. doi: 10.1055/s-0036-1571309. Epub 2016 May 5. Semin Thromb Hemost. 2016. PMID: 27148839 Review.
Mild hemophilia A (MHA) is an X-linked bleeding disorder defined by factor VIII (FVIII) levels between 5 and 40 U/dL. ...
Mild hemophilia A (MHA) is an X-linked bleeding disorder defined by factor VIII (FVIII) levels between 5 and 40 U/dL. . …
Diagnosing von Willebrand disease: genetic analysis.
Goodeve A. Goodeve A. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):678-682. doi: 10.1182/asheducation-2016.1.678. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913546 Free PMC article. Review.
More recently, next-generation sequencing has become available, with the advantage that several genes can be simultaneously analyzed where necessary, eg, for discrimination of possible type 2N VWD or mild hemophilia A. Additionally, several techniques can now …
More recently, next-generation sequencing has become available, with the advantage that several genes can be simultaneously analyzed where n …
Functional determination of emicizumab in presence of factor VIII activity.
Hamedani NS, Donners AAMT, van Luin M, Gasper S, Rühl H, Klein C, Albert T, El Amrani M, Pötzsch B, Oldenburg J, Müller J. Hamedani NS, et al. J Thromb Haemost. 2023 Dec;21(12):3490-3500. doi: 10.1016/j.jtha.2023.09.011. Epub 2023 Sep 21. J Thromb Haemost. 2023. PMID: 37741510
BACKGROUND: Accurate measurement of emicizumab in the presence of factor (F) VIII is required in patients with severe hemophilia A treated with emicizumab, as well as additional need for FVIII substitution or emicizumab prophylaxis in patients with acquired or moderate to mild …
BACKGROUND: Accurate measurement of emicizumab in the presence of factor (F) VIII is required in patients with severe hemophilia A treated w …
Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
Bowyer AE, Gosselin RC. Bowyer AE, et al. Semin Thromb Hemost. 2023 Sep;49(6):609-620. doi: 10.1055/s-0042-1758870. Epub 2022 Dec 6. Semin Thromb Hemost. 2023. PMID: 36473488 Free PMC article.
Discrepancy between one-stage and chromogenic reagents has been demonstrated in some patients with mild hemophilia A or B, the measurement of some standard and extended half-life factor replacement therapies, and the transgene expression of hemophilia A and B …
Discrepancy between one-stage and chromogenic reagents has been demonstrated in some patients with mild hemophilia A or …
The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development.
Goodeve AC, Peake IR. Goodeve AC, et al. Semin Thromb Hemost. 2003 Feb;29(1):23-30. doi: 10.1055/s-2003-37936. Semin Thromb Hemost. 2003. PMID: 12640561 Review.
This correlation is demonstrated, and a potential algorithm for predicting inhibitor development in newly diagnosed patients is presented. Many patients with mild hemophilia A have a discrepancy between the levels of FVIII:C determined by the one-stage and tw …
This correlation is demonstrated, and a potential algorithm for predicting inhibitor development in newly diagnosed patients is presented. M …
Treatment of inherited coagulation disorders.
Cohen AJ, Kessler CM. Cohen AJ, et al. Am J Med. 1995 Dec;99(6):675-82. doi: 10.1016/s0002-9343(99)80256-3. Am J Med. 1995. PMID: 7503092 Review.
Increased use of pharmacologic agents such as desmopressin acetate for patients with mild hemophilia A or type 1 von Willebrand's disease has allowed physicians to treat patients without the risk of infectious complications from plasma-derived factor concentr …
Increased use of pharmacologic agents such as desmopressin acetate for patients with mild hemophilia A or type 1 von Wi …
Management and outcomes of mild hemophiliacs and hemophilia carriers during pregnancy and peripartum period: a hemophilia treatment center experience in the United States.
Lim HI, DeSancho MT. Lim HI, et al. J Matern Fetal Neonatal Med. 2022 Dec;35(25):9759-9764. doi: 10.1080/14767058.2022.2051699. Epub 2022 Apr 12. J Matern Fetal Neonatal Med. 2022. PMID: 35414333
METHODS: Retrospective review of electronic medical records of pregnant women with mild hemophilia A or B (Factor VIII [FVIII] or Factor IX [FIX] level <0.4 IU/mL) and hemophilia A and B carriers followed at our HTC from January 2008 to October 2020. ...RE …
METHODS: Retrospective review of electronic medical records of pregnant women with mild hemophilia A or B (Factor VIII …
66 results